Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OCS Stock Forecast 2025-2026
$18.57
Current Price
$891.84M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to OCS Price Targets
+117.5%
To High Target of $40.38
+69.2%
To Median Target of $31.43
+16.4%
To Low Target of $21.61
OCS Price Momentum
0.0%
1 Week Change
+10.9%
1 Month Change
+53.9%
1 Year Change
+9.2%
Year-to-Date Change
-19.5%
From 52W High of $23.08
+72.1%
From 52W Low of $10.79
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Oculis (OCS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on OCS and similar high-potential opportunities.
Latest OCS Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, OCS has a bullish consensus with a median price target of $31.43 (ranging from $21.61 to $40.38). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $18.57, the median forecast implies a 69.2% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OCS Analyst Ratings
7
Buy
0
Hold
0
Sell
OCS Price Target Range
Low
$21.61
Average
$31.43
High
$40.38
Current: $18.57
Latest OCS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OCS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 9, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $33.00 |
| Apr 17, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $28.00 |
| Apr 17, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $32.00 |
| Mar 13, 2025 | Baird | Colleen Kusy | Outperform | Maintains | $41.00 |
| Mar 13, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $29.00 |
| Mar 13, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $28.00 |
| Jan 7, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $28.00 |
| Jan 6, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $30.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $30.00 |
| Oct 23, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $30.00 |
| Aug 28, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $30.00 |
| Jun 11, 2024 | Baird | Colleen Kusy | Outperform | Maintains | $37.00 |
| Jun 11, 2024 | Chardan Capital | Daniil Gataulin | Buy | Reiterates | $30.00 |
| Jun 11, 2024 | B of A Securities | Jason Gerberry | Buy | Maintains | $20.00 |
| Jun 11, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $30.00 |
| May 30, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $28.00 |
| May 13, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $28.00 |
| Apr 24, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $28.00 |
| Mar 19, 2024 | Baird | Colleen Kusy | Outperform | Maintains | $35.00 |
| Mar 19, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $30.00 |
Oculis Holding AG (OCS) Competitors
The following stocks are similar to Oculis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Oculis Holding AG (OCS) Financial Data
Oculis Holding AG has a market capitalization of $891.84M with a P/E ratio of 63.6x. The company generates $825,292 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -98.4% quarter-over-quarter, while maintaining an operating margin of -575,333.3% and return on equity of -102.7%.
Valuation Metrics
Market Cap
$891.84M
Enterprise Value
$1.07B
P/E Ratio
63.6x
PEG Ratio
-8.3x
Price/Sales
1,300.1x
Growth & Margins
Revenue Growth (YoY)
-98.4%
Gross Margin
N/A
Operating Margin
-575,333.3%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+10.0%
Current Ratio
2.4x
Debt/Equity
1.6x
ROE
-102.7%
ROA
-39.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Oculis Holding AG (OCS) Business Model
About Oculis Holding AG
What They Do
Develops innovative therapies for eye care.
Business Model
Oculis Holding AG focuses on the biotechnology sector, particularly on developing and commercializing ophthalmic therapies. The company generates revenue through the successful commercialization of its drug delivery technologies and treatments aimed at various eye diseases, thereby addressing unmet medical needs and improving patient outcomes.
Additional Information
Oculis is engaged in extensive research and development, targeting conditions like dry eye syndrome and diabetic macular edema. As a publicly traded company, it plays a vital role in advancing healthcare innovations in the eye care industry, contributing to improving the quality of life for patients with ocular disorders.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
49
CEO
Dr. Riad Sherif M.B.A., M.D.
Country
Switzerland
IPO Year
2023
Website
oculis.comOculis Holding AG (OCS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) delivered earnings and revenue surprises of -50.98% and 42.15%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 08, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Oculis Holding AG reported progress in R&D, highlighting positive ACUITY trial results for neuro-ophthalmology treatment and completion of DME trials. Cash reserves total $206.3 million, funding operations until early 2028.
Why It Matters
Oculis's advancements in neuro-ophthalmology and upcoming trial results may position it as a leader in a high-demand market, potentially driving stock value and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oculis Holding AG reported progress in R&D, focusing on neuroprotection treatments and diabetic macular edema. The company has $206.3M in cash, ensuring funding until early 2028.
Why It Matters
Oculis's R&D Day highlights significant advancements in neuro-ophthalmology and diabetic eye treatments, potentially positioning the company for market leadership in high-demand areas.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oculis Holding AG reported a quarterly loss of $0.77 per share, exceeding the estimate of $0.51, and worsening from a loss of $0.44 per share a year earlier.
Why It Matters
Wider-than-expected losses signal potential operational or market challenges, which may lead to decreased investor confidence and impact Oculis Holding AG’s stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Oculis Holding AG will hold its 2025 Annual General Meeting on June 4, 2025, in Zug, Switzerland, at 3:00 p.m. CEST. Investors may attend to discuss company matters.
Why It Matters
The announcement of Oculis Holding AG's Annual General Meeting may signal key corporate decisions and performance updates that can impact stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oculis Holding AG (OCS) is anticipated to lack the necessary factors for a potential earnings beat in its upcoming report. Investors should prepare for key expectations.
Why It Matters
Oculis Holding AG's lack of crucial factors for an earnings beat may signal poor performance, potentially leading to stock price declines and impacting investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Oculis Holding AG will present at upcoming investor conferences, focusing on innovations in ophthalmic and neuro-ophthalmic diseases with unmet medical needs.
Why It Matters
Oculis's participation in investor conferences signals potential growth opportunities and increased visibility, which may influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About OCS Stock
What is Oculis Holding AG's (OCS) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Oculis Holding AG (OCS) has a median price target of $31.43. The highest price target is $40.38 and the lowest is $21.61.
Is OCS stock a good investment in 2025?
According to current analyst ratings, OCS has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.57. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OCS stock?
Wall Street analysts predict OCS stock could reach $31.43 in the next 12 months. This represents a 69.2% increase from the current price of $18.57. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Oculis Holding AG's business model?
Oculis Holding AG focuses on the biotechnology sector, particularly on developing and commercializing ophthalmic therapies. The company generates revenue through the successful commercialization of its drug delivery technologies and treatments aimed at various eye diseases, thereby addressing unmet medical needs and improving patient outcomes.
What is the highest forecasted price for OCS Oculis Holding AG?
The highest price target for OCS is $40.38 from at , which represents a 117.5% increase from the current price of $18.57.
What is the lowest forecasted price for OCS Oculis Holding AG?
The lowest price target for OCS is $21.61 from at , which represents a 16.4% increase from the current price of $18.57.
What is the overall OCS consensus from analysts for Oculis Holding AG?
The overall analyst consensus for OCS is bullish. Out of 6 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $31.43.
How accurate are OCS stock price projections?
Stock price projections, including those for Oculis Holding AG, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 4:16 PM UTC